Evidence map›Paper›PMID 37964011›Full record

ArticleScientific reports2023

Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma.

Danny Lascano, Michael J Zobel, William G Lee, Stephanie Y Chen, Abigail Zamora, Grace E Asuelime, So Yung Choi, Antonios Chronopoulos, Shahab Asgharzadeh, Araz Marachelian and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Danny Lascano *Division of Pediatric Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Michael J Zobel *Division of Pediatric Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
William G LeeDivision of Pediatric Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Stephanie Y ChenDivision of Pediatric Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Abigail ZamoraDivision of Pediatric Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Grace E AsuelimeDivision of Pediatric Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
So Yung ChoiBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Antonios ChronopoulosDivision of Hematology, Oncology and Blood and Marrow Transplantation, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Shahab AsgharzadehDivision of Hematology, Oncology and Blood and Marrow Transplantation, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Araz MarachelianDivision of Hematology, Oncology and Blood and Marrow Transplantation, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jinseok ParkDivision of Hematology, Oncology and Blood and Marrow Transplantation, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Michael A SheardThe Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Eugene S KimDivision of Pediatric Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA. eugene.kimx@cshs.org.
Children's Hospital of Los Angeles · USUniversity of Southern California · USCedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C-C motif chemokine ligand 2 (CCL2) is a monocyte chemoattractant that promotes metastatic disease and portends a poor prognosis in many cancers. To determine the potential of anti-CCL2 inhibition as a therapy for recurrent metastatic disease in neuroblastoma, a mouse model of minimal residual disease was utilized in which residual disease was treated with anti-CCL2 monoclonal antibody with etoposide. The effect of anti-CCL2 antibody on neuroblastoma cells was determined in vitro with cell proliferation, transwell migration, and 2-dimensional chemotaxis migration assays. The in vivo efficacy of anti-CCL2 antibody and etoposide against neuroblastoma was assessed following resection of primary tumors formed by two cell lines or a patient-derived xenograft (PDX) in immunodeficient NOD-scid gamma mice. In vitro, anti-CCL2 antibody did not affect cell proliferation but significantly inhibited neuroblastoma cell and monocyte migration towards an increasing CCL2 concentration gradient. Treatment of mice with anti-CCL2 antibody combined with etoposide significantly increased survival of mice after resection of primary tumors, compared to untreated mice.

Indexed as

NeuroblastomaAnimalsCell Line, TumorChemokine CCL2ChemokinesEtoposideHumansLigandsMiceMice, Inbred NODNeoplasm, ResidualCCL2 protein, humanChemokine CCL2ChemokinesEtoposideLigands

Identifiers

PMID37964011
PMCPMC10645976
OpenAlexW4388672329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.